Shares of Asian drugmakers drop after Trump threatens tariffs

Core Viewpoint - Shares of Asian drugmakers experienced a decline following U.S. President Donald Trump's announcement of potential 100% tariffs on imports of branded pharmaceuticals starting October 1, contingent upon the establishment of U.S. manufacturing plants by their producers [1] Group 1 - The announcement by President Trump poses a significant threat to Asian drugmakers, as it could lead to increased costs and reduced competitiveness in the U.S. market [1] - The tariffs are aimed at encouraging pharmaceutical companies to invest in domestic manufacturing, which could reshape the industry landscape [1] - The potential implementation of these tariffs may lead to a broader impact on global supply chains and pricing strategies within the pharmaceutical sector [1]